Sebetralstat Dosage

Medically reviewed by Drugs.com. Last updated on Aug 12, 2025.

Usual Adult Dose for Hereditary Angioedema

600 mg orally at the earliest recognition of an acute hereditary angioedema (HAE) attack

• Second dose: 600 mg may be taken at least 3 hours after the first dose if response is inadequate or if symptoms recur or worsen

Maximum dose: 1200 mg in any 24-hour period

Use: For the treatment of acute attacks of HAE

Usual Pediatric Dose for Hereditary Angioedema

12 years and older: 600 mg orally at the earliest recognition of an acute HAE attack

• Second dose: 600 mg may be taken at least 3 hours after the first dose if response is inadequate or if symptoms recur or worsen

Maximum dose: 1200 mg in any 24-hour period

Use: For the treatment of acute attacks of HAE

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Mild liver dysfunction (Child-Pugh Class A): No adjustment recommended
Moderate liver dysfunction (Child-Pugh Class B): 300 mg orally at the earliest recognition of an acute HAE attack

• Second dose: 300 mg may be taken at least 3 hours after the first dose if response is inadequate or if symptoms recur or worsen.

Severe liver dysfunction (Child-Pugh Class C): Not recommended

Dose Adjustments

Dose Modification for Concomitant Use with CYP450 3A4 Inhibitors:

• Weak CYP450 3A4 inhibitors: No adjustment recommended
• Moderate CYP450 3A4 inhibitors: 300 mg orally at the earliest recognition of an acute HAE attack
• Second dose: 300 mg may be taken at least 3 hours after the first dose if response is inadequate or if symptoms recur or worsen
• Strong CYP450 3A4 inhibitors: Not recommended

Dose Modification for Concomitant Use with CYP450 3A4 Inducers:

• Weak CYP450 3A4 inducers: No adjustment recommended
• Moderate and Strong CYP450 3A4 inducers: Not recommended

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 12 years.

Dialysis

Data not available

Other Comments

Storage requirements:

• Store at 20C to 25C (68F to 77F), with excursions permitted between 15C and 30C (59F to 86F).

General:

• Clinical studies did not include enough patients 65 years and older to determine whether they respond differently from younger patients.
• Report suspected adverse reactions to KalVista Pharmaceuticals, Inc. at 1-855-258-4782 or US FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Patient advice:

• Read the US FDA-approved patient labeling (Patient Information).

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer